mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...
After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...
Survival disparities in small intestine carcinoid tumors: A SEER-based analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include ...
with longer progression-free survival compared with placebo in patients with well-differentiated neuroendocrine tumors and low tumor burden. ...octreotide LAR significantly lengthens the median ...
"The minimal improvement in survival in recent years is in part related to more people being diagnosed with incidentally detected, well differentiated neuroendocrine tumors, which are less ...
The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.
Hosted on MSN9mon
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine TumorsNETs are a type of cancer that originates in neuroendocrine ... in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and ...
Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback